Dasatinib

Catalog No.S1021 Synonyms: BMS-354825

Dasatinib Chemical Structure

Molecular Weight(MW): 488.01

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 147 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 64 Publications

12 Customer Reviews

  • Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta.

    Cell Res 2011 21, 1080-1087. Dasatinib purchased from Selleck.

    Cytotoxicity by Dasatinib and Nutlin-3 used alone or in combination in B-CLL patient leukemic cells. B-CLL patient leukemic cells were exposed to serial doses of Dasatinib or Nutlin- 3 used either alone or in combination, with a fixed ratio, for 48 hours. Dose-effect plots, to determine drug efficacy, are shown for representative B-CLL samples, including 3 patients carrying 17p- (Pt. #7, Pt. #8, and Pt. #10). The decrease of cell viability, labeled "effect" on the Y-axis, was determined in assays done at least twice in duplicate.

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

  • Dasatinib interferes with the p53 transcriptional activity induced by Nutlin-3. Leukemic cell lines were exposed for 24 hours to Dasatinib (10 μM) and Nutlin-3 (10 μM), used either alone or in combination, as indicated. Levels of p53 (A), MDM2 and p21 (B) were assessed by Western blot analysis of total cell lysates. Representative examples of Western blot results are shown. Tubulin staining is shown as loading control; after densitometric analyses, p53 as well as MDM2 and p21 protein levels are expressed as folds of protein modulation, by the indicated treatments, with respect to the control untreated cultures set to 1 (hatched line). *P < 0.05 with respect to the Nutlin-3-treated cultures.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

    Role of Akt in Dasatinib cytotoxicity and in DasatinibtNutlin-3 synergy. A, whole cell lysates were prepared from EHEB and BJAB cell lines treated (for 16 hours) as indicated, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls (set at 100) on the same membrane. The analysis of modulation of phosphorylation signals for P-ERK1/2, P-p38, and P-Akt are reported (*P < 0.05). Validation of phospho-kinase array results was carried out by Western blot analysis of P-Akt levels.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

  • Impact of the TKI erlotinib, lapatinib, dasatinib, and sorafenib on the viability of MDS/AML cells. MOLM-13 (A) and HL-60 (B) cells were incubated with the indicated doses (given in mM below the x-axis) of the 4 TKI, and cellular viability was assessed by MTT assay after 24, 48 and 72 h of incubation. Changes in viability are given as percentage of cells as compared to non-treated control samples. This experiment was repeated at least three times, yielding comparable results. Graphs show representative results of one experiment carried out in duplicates (mean standard deviation).

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

    Capacity of the TKI to overcome the AML-typical differentiation blockage. The myeloid cell lines MOLM-13 and HL-60 were incubated for 6 days with 0.01% DMSO (serving as a negative solvent control), 1 μM of ATRA (serving as a positive control), as well as with the indicated doses of the four TKI. (A) Representative May -Gruenwald -Giemsa staining of MOLM-13 cells, (B) quantitation of the percentage of MOLM-13 cells exhibiting at least two morphological signs of differentiation (that is a decrease in cytoplasmic basophilia, a reduction of the nucleo-cytoplasmic ratio, appearance of nuclear lobulation and/or cytoplasmic granules). Percentages were evaluated by examining at least 100 cells/condition; (C) representative FACS overlays of MOLM-13 cells depicting TKI-induced CD11b expression (black line) as compared to the isotype (shaded grey); (D) quantitation of TKI-induced CD11b-expression in MOLM-13 cells; (E) representative slides depicting morphology/staining of MOLM-13 cells assessed in the NBT-reduction assay; (F) respective quantitative assessment demonstrating the NBT-reducing capacity under the different drugs; (G) representative May-Gruenwald-Giemsa staining of HL-60 cells.

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

  • Effect of dasatinib on endothelial cell actin fiber organization. Subconfluent human microvascular endothelial cells‐1 were treated with dimethyl sulfoxide (A) or dasatinib (B), fixed, permeabilized and stained with phalloıdin (green) for F‐actin or FAK (red) for adhesion plaques. Images were taken in a confocal microscope (1000X).

    Cancer Med, 2017, 6(4):809-818. Dasatinib purchased from Selleck.

    Cytotoxicity by Dasatinib treatment in leukemic cells.Leukemic cell lines were exposed to Dasatinib (10 μM). Upon treatment, cell viability (a) was calculated as percentage with respect to the control vehicle cultures (set to 100% for each cell line) and induction of apoptosis (b) was calculated as percentage of Annexin V+/PI+ cells after 48 h of treatment.

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Human phospho-kinase array analysis in response to Dasatinib treatment. Whole cell lysates were prepared from EHEB (p53wt) and BJAB (p53mut) B cell lines, either left untreated or exposed to Dasatinib for 24 h, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls on the same membrane. In a, intense decreases of signal of P-p38, PERK1/2 and P-CREB in response to Dasatinib are indicated by arrows in the membranes, and intensity of corresponding spots are reported as graphics. In b, analysis of modulation of phosphorylation of STAT family members in response to Dasatinib (spots not shown). The means±SD of three independent experiments are shown. Asterisk indicates P<0.05 against untreated.

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

    Cells were either left untreated (Unt.) or exposed to Dasatinib (Das.) for 24 h. Equal amounts of cell lysates were analyzed for ERK1/2, p38 and CREB phosphorylation by Western blot using antibodies specific for the native form of the kinases and for residues that are phosphorylated (P-) in each kinase upon activation. One of three experimentswith similar results is shown. Protein bands were quantified by densitometry and level of PERK1/2, P-p38 and P-CREB expressed as arbitrary units,were calculated for each cell line after normalization to total ERK1/2, p38 and CREB respectively

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Inhibition of cell growth upon culturing of primary bone marrow cells from an EMS patient and a healthy control in presence of TKIs in vitro. EMS cells showed reduced cell growth compared to the healthy control cells when cultured with ponatinib, dovitinb or dasatinib. Cell growth was evaluated after 72 hours in culture. All samples were normalized to DMSO controls. Non-linear regression curves were fitted for evaluation of IC50 values. Error bars represent mean values and standard deviation of the analyzed replicates.

    Eur J Haematol, 2017, 99(5):442-448. Dasatinib purchased from Selleck.

    Cell vability test result. Different cell lines (A2C12, Beta D5, Gamma A3, Gamma D12, A549, CaCo2,Hep G2) were treated with different concentration of Dasatinib.

     

     

    Dr. Thomas Kruwel of Fraunhofer-Institute for Toxicology and Experimental Medicine-Dasatinib (BMS-354825) purchased from Selleck. Dasatinib purchased from Selleck.

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Description Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.
Targets
Abl [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
c-Kit (D816V) [2]
(Cell-free assay)
c-Kit (wt) [2]
(Cell-free assay)
0.6 nM 0.8 nM 37 nM 79 nM
In vitro

Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. [1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. [3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
M07ep210 NX;zOmdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fKU|czKGh? NH7UbG5FVVOR NFTVWI9KSzVyPUCuNFAxODdizszN MVWxO|k2PjB6MB?=
K562 NV\uNVFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkO5O|IhcA>? MlzYSG1UVw>? NE\v[nhKSzVyPUCuNFAyKM7:TR?= NG\EdncyPzl3NkC4NC=>
M07e NYr3S5F1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PSZlczKGh? MXHEUXNQ MlLZTWM2OD1yLkCwNVIh|ryP NHjlR2gyPzl3NkC4NC=>
ALL3 Mm\JR5l1d3SxeHnjJGF{e2G7 NYXQWoxLOC5zzszN MnLIO|IhcA>? MV;EUXNQ M3HEdGlEPTB;MD6wNFA1KM7:TR?= MYqxPVg5QTV2MB?=
CML M4\MPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLxNlAhdWmw M2PaXWROW09? NFzrPJBKSzVyPUCuNFAyKM7:TR?= NYnT[Fc{OTl{MUmwNVY>
BA/F3 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDsO|IhcA>? Mn:4SG1UVw>? Mn;vTWM2OD14LkW4PUDPxE1? MnPCNlMxQDh4NES=
BA/F3 MnTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zLPVczKGh? MnvvSG1UVw>? NEDyOnZKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlGvSlMh[2WubIOg[ZhxemW|c3nu[{BD[3JvQXLsJG0{PTGWIH31eIFvfCC5aYToJGlEPTBib3[gNE4xODB6M988US=> NHLmV5QzOzB6OE[0OC=>
BA/F3 M{HQWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37P[|czKGh? NWfkOXNOTE2VTx?= NVHlc45RUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKEKlcj3BZowhf2m2aDDJR|UxKG:oIECuNFA1Pc7:TR?= MVKyN|A5QDZ2NB?=
BA/F3 M3X3RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;keJU4OiCq NUL3d2RETE2VTx?= NF3FVVZKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlGvSlMh[2WubIOg[ZhxemW|c3nu[{BD[3JvQXLsJHQ{OTWLIH31eIFvfCC5aYToJGlEPTBib3[gNU44OTUQvF2= M3npV|I{ODh6NkS0
BA/F3 M1PqUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTEPVhHPzJiaB?= Mom2SG1UVw>? MWrJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBHPDh4UzDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECwPe69VQ>? M2\PXFI{OzBzN{Cz
BA/F3 NYTUdG85T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFniPG84OiCq NFTjd|BFVVOR MUPJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBGOjV3SzDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECzNu69VQ>? NGjnUY4zOzNyMUewNy=>
BA/F3 MmX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjlNno4OiCq NHLSTphFVVOR MUfJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBIOjVyRTDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMEC1Ne69VQ>? MoLqNlM{ODF5MEO=
BA/F3 NX;Mb5lUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHKO|IhcA>? MWHEUXNQ MkLrTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhWTJ3MligcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwPO69VQ>? MYOyN|MxOTdyMx?=
BA/F3 M2CxN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfIcIYxPzJiaB?= MkLKSG1UVw>? MX7JcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBGOzV7VjDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECxN:69VQ>? MXKyN|MxOTdyMx?=
BA/F3 MoSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTYZ21kPzJiaB?= NWLjNo1pTE2VTx?= NG\Lb2VKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5Nqdmdid3ns[EB1gXCnIFLDVk1CSkxiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECxPe69VQ>? M2rrN|I{OzBzN{Cz
BA/F3 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXucXM4OiCq MoLHSG1UVw>? NITqTXlKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCC\MkWzTEBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFAzO87:TR?= MVWyN|MxOTdyMx?=
BA/F3 NH\LR21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLoTlF{PzJiaB?= NEGwNZZFVVOR MV\JcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBVOzF3STDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDNwNt88US=> M1PUdFI{OzBzN{Cz
BA/F3 NIrySo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUC4eG5UPzJiaB?= MorTSG1UVw>? M13UdWlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh[XO|ZYPz[YQh[XNiZ4Lve5RpKEmwaHnibZRqd25id3n0bEBKSzVyIH;mJFIvPc7:TR?= MlewNlM{ODF5MEO=
T cell NYPTXG1CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYS3NkBp MkOySG1UVw>? MmnUTY5pcWKrdIOgZY51cSCFREOtJIFv\CCjboTpJGNFOjhvaX7keYNm\CCWIHPlcIwheHKxbHnm[ZJifGmxbjD3bZRpKEmFNUCgc4YhOC5yMEROwG0> NFHFZ2kyPzF3NEWxNi=>
WiDr NIfXR|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zJblczKGh? M3j4SGROW09? NFP2RodKSzVyPUCuNFUzKM7:TR?= NHjoT|QyPTZzNUWxNi=>
PC3 Mlz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3OO|IhcA>? MmLBSG1UVw>? MWrJR|UxRTBwMEC5OEDPxE1? M{W5SVE2PjF3NUGy
MDA-MB-231 NFHr[I5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTydG5[PzJiaB?= MV3EUXNQ MWrJR|UxRTBwMEGyJO69VQ>? NFvQPGgyPTZzNUWxNi=>
Hs578T MmnSR5l1d3SxeHnjJGF{e2G7 M1LwWFczKGh? NXfSelNoTE2VTx?= NIXnbFBIUTVyPUCuNFMh|ryP NUn3TGVmOjRyMUWzNlc>
HMEC MUDDfZRwfG:6aXOgRZN{[Xl? NEj2So04OiCq MojFSG1UVw>? NGfGN2FIUTVyPUGuPEDPxE1? M3PKRVI1ODF3M{K3
DU145 MnXIR5l1d3SxeHnjJGF{e2G7 NWD0PGdLPzJiaB?= MYfEUXNQ MULHTVUxRTBwMU[g{txO MWOyOFAyPTN{Nx?=
U251 M1zKdmN6fG:2b4jpZ{BCe3OjeR?= MVm3NkBp NF:xWY9FVVOR M1XSNGdKPTB;Mj64NUDPxE1? NHzKcogzPDBzNUOyOy=>
NCI60 M4nSOWN6fG:2b4jpZ{BCe3OjeR?= NWXyd2d[PzJiaB?= NV3HeVNLTE2VTx?= NGezNVlIUTVyPUWuO{DPxE1? MXiyOFAyPTN{Nx?=
MALME-3M NX61RoNyS3m2b4TvfIlkKEG|c3H5 NF\PXoI4OiCq NIjUdHZFVVOR M4HsUmdKPTB;Nj62NUDPxE1? M3TDSFI1ODF3M{K3
KM12 M{LkWWN6fG:2b4jpZ{BCe3OjeR?= MUe3NkBp MYrEUXNQ MnzYS2k2OD15LkS0JO69VQ>? MYeyOFAyPTN{Nx?=
SW620 NHrhSXFEgXSxdH;4bYMhSXO|YYm= MnfsO|IhcA>? MYLEUXNQ Mn;4S2k2OD16LkSzJO69VQ>? NV[4Z|BTOjRyMUWzNlc>
RXF 393NL NUDyeVhrS3m2b4TvfIlkKEG|c3H5 NEC1OJE1KGSjeYO= MmLOSG1UVw>? NI\HNFNKSzVyPUCuNFIyPyEQvF2= NV3kcXBUOjN{NUOwO|Q>
LXFA 983L MXTDfZRwfG:6aXOgRZN{[Xl? M1jpTlQh\GG7cx?= M4TkTGROW09? NX3yXG5SUUN3ME2wMlA2PjVizszN MXqyN|I2OzB5NB?=
PRXF DU145 NUf0WXZCS3m2b4TvfIlkKEG|c3H5 M1HBZVQh\GG7cx?= MXzEUXNQ M2HYSWlEPTB;MD6wOlI{KM7:TR?= MYGyN|I2OzB5NB?=
PAXF 1657L M{n5UGN6fG:2b4jpZ{BCe3OjeR?= MWS0JIRigXN? MV\EUXNQ NIraVllKSzVyPUCuNVIyKM7:TR?= MXeyN|I2OzB5NB?=
CXF 1103L MX3DfZRwfG:6aXOgRZN{[Xl? NX75[FlJPCCmYYnz M1nIWGROW09? NGfxO|dKSzVyPUSuN|Yh|ryP NVTFSVlzOjN{NUOwO|Q>
GXF251L M2fwcGN6fG:2b4jpZ{BCe3OjeR?= NF\MV2U1KGSjeYO= MVTEUXNQ NILUOoFKSzVyPUKuNlUh|ryP NV\oRXZ7OjN{NUOwO|Q>
NCI-H23 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHCW5VXPzJiaB?= NV60enFmTE2VTx?= MV3JR|UxRTJwMkeg{txO MVSyN|UzOTB{MB?=
HCT116 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXq3NkBp MVvEUXNQ Mkj4TWM2OD1{LkOg{txO M2nCPFI{PTJzMEKw
MCF7 NIn1dZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLTfYI1PzJiaB?= M3\DUGROW09? NIDVbGRKSzVyPUKuOVch|ryP NX3UdWVTOjN3MkGwNlA>
NCI-H460 MlXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX[3NkBp MofvSG1UVw>? MknaTWM2OD16Lkm5JO69VQ>? NWDTcVdVOjN3MkGwNlA>
DLD1 M2\VeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1n5b|czKGh? NXziTGQxTE2VTx?= NU\rPVBQUUN3ME20MlYh|ryP MYqyN|U3Pzl4MB?=
NCI-H661 Mn3uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYm3NkBp MornSG1UVw>? Mo[1TWM2OD15Lkig{txO MWGyN|U3Pzl4MB?=
A549 NYDZfWpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLpO|IhcA>? NFjFdWRFVVOR NELFXWNKSzVyPUiuNkDPxE1? MWiyN|U3Pzl4MB?=
U937 M2TVXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmT2O|IhcA>? NG\wO2hFVVOR MlL3TWM2OD1zMj6yJO69VQ>? M2L3[lI{PTZ5OU[w
HEK293 NUDWUnUzTnWwY4Tpc44hSXO|YYm= M3i0VVExyqEQvF2= MmjxSG1UVw>? MkX2TY5lfWOnczDibY5lcW6pIHHm[olvcXS7IITvJIh2dWGwIH\1cIwudGWwZ4ToJGhqey22YXfn[YQhVXm2MTDrbY5ie2ViZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyC5aYToJGlEPTBib3[gNE4xPjQQvF2= NVz5b2d6OjJ5N{C2NVA>
HUVEC NUHjSZk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYWwMlE2yqEQvF2= NHTRU3k4OiCq MkjjSG1UVw>? NIDWT2pKdmS3Y3XzJIFvfGmjbnfpc4dmdmmlIHHjeIl3cXS7IHnuJGhWXkWFIHPvMYN2dHS3cnXkJJdqfGhidnHzZ5Vt[XJic33vc5RpKG23c3Ps[UBk\WyuczDhd5Nme3OnZDDhd{BKdmirYnn0bY9vKG:oIHPlcIwh\3Kxd4ToJIF1KDBwMUWgeW0> NVL2W4dHOjJ6NUO5PVM>
HUVEC NHvMdGNHfW6ldHnvckBCe3OjeR?= NEnXdVYyPcLizszN NGr0cWk4OiCq M3fyRWROW09? NV2yblcxUW6mdXPld{BidnSrYX7nbY9o\W6rYzDhZ5Rqfmm2eTDpckBJXV[HQzDjc{1kfWy2dYLl[EB4cXSqII\hd4N2dGG{IIPtc491cCCvdYPjcIUh[2WubIOgZZN{\XO|ZXSgZZMhUW6qaXLpeIlwdiCxZjDu[ZR4d3KtIH\vdo1ifGmxbjDheEAyNjhidH:gNVUhfU1? M1W5RVIzQDV|OUmz
Plasmodium falciparum M33LN2Z2dmO2aX;uJGF{e2G7 M2XIclExyqEQvF2= M{\FSVE2KG2rbh?= MYTEUXNQ M1PlNWlvcGmkaYTzJHBt[XOvb3TpeY0h\mGuY3nwZZJ2dSCycn;sbYZmemG2aX;uJIJ6KGmwaHnibZRqdmdidHjlJGZ2dmO2aX;uJI9nKFCoQ1TQT|EheHKxdHXpckB4cXSqIFnDOVAhd2ZiMT6xO:69VQ>? NFf3SYczPDV3MEOzNC=>
PC3 MX7GeY5kfGmxbjDBd5NigQ>? MYWwMlEh|ryP MkLROUBp MXXEUXNQ NGO5fmNKdmirYnn0d{BpfW2jbjDQR|Mh[2WubDDh[Ihme2mxbjDheEAyODBibl2= MVKxPVQ3Ojl5NR?=
DU145 MmTBSpVv[3Srb36gRZN{[Xl? NUTxSnc4OC5zIN88US=> MkToOUBp NIfh[nJFVVOR M3jqdWlvcGmkaYTzJIh2dWGwIFTVNVQ2KGOnbHygZYRp\XOrb36gZZQhOTByIH7N MWSxPVQ3Ojl5NR?=
PC3 M1zRTWtqdmG|ZTDBd5NigQ>? M4PYU|AvOSEQvF2= M2Dvc|UhcA>? NXPhNZNZTE2VTx?= NEG4U4dKdmirYnn0d{BkW3KlIHnuJIh2dWGwIGDDN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZicHjvd5Bpd3K7bHH0[YQhW3KlIGm0NVYhdGW4ZXygZZQhOTByIH7N NWTzZo12OTl2NkK5O|U>
DU145 MWLLbY5ie2ViQYPzZZk> MWKwMlEh|ryP MXq1JIg> MX\EUXNQ NFfEeZdKdmirYnn0d{BkW3KlIHnuJIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCxZjDwbI9{eGixconsZZRm\CCVcnOgXVQyPiCuZY\lcEBifCBzMECgcm0> NWPyXmtCOTl2NkK5O|U>
PC3 M4HiU2tqdmG|ZTDBd5NigQ>? M4LtTlAvOSEQvF2= MX[1JIg> NYLCOpBpTE2VTx?= NEf2c5lKdmirYnn0d{BkW3KlIHnuJIh2dWGwIGDDN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZicHjvd5Bpd3K7bHH0[YQhTkGNIGm1O|YwYTV5NzDs[ZZmdCCjdDCxNFAhdk1? MWqxPVQ3Ojl5NR?=
DU145 MXrLbY5ie2ViQYPzZZk> M1jydVAvOSEQvF2= NXvPO3ZtPSCq NH21TVNFVVOR NEnjd|BKdmirYnn0d{BkW3KlIHnuJIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCxZjDwbI9{eGixconsZZRm\CCIQVugXVU4Pi:\NUe3JIxmfmWuIHH0JFExOCCwTR?= NH74OIQyQTR4Mkm3OS=>
Huh7 NVzWW486SW62aY\pdoFtKEG|c3H5 M3joPFIvPSEQvF2= M4H5SVQh\GG7cx?= MkKySG1UVw>? NIfmVY5KdmirYnn0d{B3cXKjbDDzdJJm[WRiaX6gSIVv\3WnII\pdpV{NWmwZnXjeIVlKGi3bXHuJGh2cDdiY3XscJMh[XO|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJI9nKH[rcnHsJIVvfmWub4DlJJBzd3SnaX6ge4l1cGmwIIDldolvfWOuZXHyJJJm\2mxbjDheEAzNjVidV2= NF6zXW0yPzN4ME[3Oi=>
C6/36 MnfBRY51cX[rcnHsJGF{e2G7 MVeyMlUh|ryP NHXqcmg1KGSjeYO= NU\xb5lvTE2VTx?= M3[2UmlvcGmkaYTzJJZqemGuIIPwdoVi\CCrbjDE[Y5ofWVidnnyeZMucW6oZXP0[YQh[XOrYX6geIlo\XJibX;zdZVqfG9iQ{[vN|Yh[2WubIOgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIH;mJJZqemGuIHXueoVtd3CnIIDyc5RmcW5id3n0bIlvKHCncnnueYNt\WG{IILl[4lwdiCjdDCyMlUhfU1? NE\JRVYyPzN4ME[3Oi=>
U937 M2fqWmZ2dmO2aX;uJGF{e2G7 NVzKSZY6OSEQvF2= NXvFVFZlOSCq MVjEUXNQ Mn\SVoVlfWOnczDiZZNidCCWTl\hcJBp[SC{ZXzlZZNmKGmwIHj1cYFvKFV7M{egZ4VtdHN? Ml\JNVc3QDRyOUm=
U937 MlLOSpVv[3Srb36gRZN{[Xl? MXmxJO69VQ>? MXuxJIg> MWXEUXNQ MYrS[YR2[2W|IFzQV{1qdmS3Y3XkJHRPTmGucHjhJJJmdGWjc3WgbY4hcHWvYX6gWVk{PyClZXzsdy=> M4q2U|E4Pjh2MEm5
murine mast cell MkLpSpVv[3Srb36gRZN{[Xl? MkTsNUDPxE1? NX;YUIgyOjRiaB?= MVzEUXNQ Mom0TY5pcWKrdIOgZY51cWenbj3pcoR2[2WmIFnMOkB{\WO{ZYTpc44hcW5iSXfFJJBzcW2nZDDtc5V{\SCvYYP0JINmdGy|IHH0JFEhfU1? MWCxO|Y5PDB7OR?=
BV-173 NWPkNHJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrRbmhnUUN3ME2wMlAxODByMEGwPUDPxE1? MWLTRW5ITVJ?
K-562 M1rZUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXJTlFUUUN3ME2wMlAxODByMEK2OkDPxE1? Mn\lV2FPT0WU
BL-70 M2Cz[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTBwMECwNFAxQDJ{IN88US=> MXTTRW5ITVJ?
EM-2 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnRd4I6UUN3ME2wMlAxODByMUC4JO69VQ>? NUPZSXY6W0GQR1XS
LAMA-84 NWDjdmlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTBwMECwNFA{OjFizszN MUHTRW5ITVJ?
MEG-01 M1zEcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLPTWM2OD1yLkCwNFAxQThizszN NIToTFNUSU6JRWK=
EoL-1-cell NUDHe|RuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTBwMECwNFE{OSEQvF2= MlvxV2FPT0WU
CTV-1 MkWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7yTWM2OD1yLkCwNFA1ODRizszN M2HiXHNCVkeHUh?=
TE-15 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfQfWdEUUN3ME2wMlAxPTh7IN88US=> MXjTRW5ITVJ?
NOS-1 NYP1[ldnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTBwMEC2NVMh|ryP M1XVXXNCVkeHUh?=
D-336MG MmrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTBwMEC2N{DPxE1? NGLtfVFUSU6JRWK=
LB1047-RCC NF\oPHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfOVIhKSzVyPUCuNFA6QDlizszN M3rVeHNCVkeHUh?=
LB996-RCC Moi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2W5NmlEPTB;MD6wNFk6OSEQvF2= MV3TRW5ITVJ?
SW982 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{j1Z2lEPTB;MD6wNVEyPSEQvF2= NWjlXYh5W0GQR1XS
TK10 NUO3XpByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTBwMEGxO|Qh|ryP MlTUV2FPT0WU
A704 M4H2Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXxW5ZUUUN3ME2wMlAyPDlzIN88US=> NEXEVXVUSU6JRWK=
TE-8 NETyZoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjVPG5KSzVyPUCuNFE2PzZizszN MmDuV2FPT0WU
DOHH-2 MnWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTBwMEG3NVkh|ryP MlHSV2FPT0WU
HOP-62 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nxfGlEPTB;MD6wNVg{PCEQvF2= MVLTRW5ITVJ?
TE-12 NHTNcXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTCTWM2OD1yLkCxPFYyKM7:TR?= M3TybXNCVkeHUh?=
KGN MmH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnse4pKSzVyPUCuNFE6PDJizszN MY\TRW5ITVJ?
NCI-H1648 M2C4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTBwMEKwNVEh|ryP NEO3SFJUSU6JRWK=
OS-RC-2 M1O0cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPRTWM2OD1yLkCyNFMh|ryP NF:0VopUSU6JRWK=
GB-1 MnX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvOOXNKSzVyPUCuNFIyPTdizszN MUPTRW5ITVJ?
RXF393 MnHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTBwMEKzOVch|ryP NFLWdYJUSU6JRWK=
LC-2-ad MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmThTWM2OD1yLkCyOVg3KM7:TR?= NHXXVGRUSU6JRWK=
KS-1 MojWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTBwMEK3N{DPxE1? MXHTRW5ITVJ?
ETK-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTBwMEK4N|Ih|ryP MmHPV2FPT0WU
SW954 Ml\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTBwMEK5Nlch|ryP MkXSV2FPT0WU
Becker NIHFSFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTBwMEOwNFMh|ryP M{DseHNCVkeHUh?=
MZ1-PC MmTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfXdoJKSzVyPUCuNFMyOTlizszN M33GdXNCVkeHUh?=
ES6 M2Pl[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknTTWM2OD1yLkCzNVk{KM7:TR?= NFTDZmZUSU6JRWK=
KURAMOCHI MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXJTWM2OD1yLkCzOFg4KM7:TR?= MnXpV2FPT0WU
CGTH-W-1 NFvOW45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;ITWlEPTB;MD6wN|U1QCEQvF2= NXfXV4Y6W0GQR1XS
VA-ES-BJ MnHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml[xTWM2OD1yLkCzPVAzKM7:TR?= M{fSXXNCVkeHUh?=
LXF-289 M3r2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTBwMEO5OVYh|ryP MYPTRW5ITVJ?
MPP-89 M1y1S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zMZWlEPTB;MD6wOFA1QSEQvF2= M3;WbXNCVkeHUh?=
SW872 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmS1TWM2OD1yLkC0NVYyKM7:TR?= MknkV2FPT0WU
SNB75 NEDxUJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\3Z4JKSzVyPUCuNFQ1OzVizszN M{O2PXNCVkeHUh?=
PSN1 MlnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfPdolkUUN3ME2wMlA1PDd2IN88US=> M2npfHNCVkeHUh?=
LB831-BLC NWPDSGVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTBwMES2NFkh|ryP M4HwSXNCVkeHUh?=
MFH-ino MlfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTBwMES3NlQh|ryP MljXV2FPT0WU
TGBC24TKB MkH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnBb4RKSzVyPUCuNFQ4PjFizszN MlL1V2FPT0WU
A388 NXzX[plST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTBwMEWwPVUh|ryP MUTTRW5ITVJ?
BB30-HNC M3y3SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3BR|JKSzVyPUCuNFU1OzdizszN M4jDO3NCVkeHUh?=
GI-ME-N M3PZOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTBwME[xNVgh|ryP M3HxTHNCVkeHUh?=
TGBC1TKB NXy5O|YxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnuxTWM2OD1yLkC2NVY1KM7:TR?= NVSwdlRvW0GQR1XS
TE-10 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHnTWM2OD1yLkC2N|U4KM7:TR?= NVrYdnhGW0GQR1XS
A498 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjSTWM2OD1yLkC3Nlg1KM7:TR?= NV7KOok4W0GQR1XS
TE-11 M4nGWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfBTWM2OD1yLkC3PFU5KM7:TR?= M37iZnNCVkeHUh?=
BB65-RCC MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrjeHJFUUN3ME2wMlA5OjJ5IN88US=> NIrqPVJUSU6JRWK=
C2BBe1 Mm\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfic5lKSzVyPUCuNFg{ODhizszN M2fLVHNCVkeHUh?=
NCI-H747 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjVXIJKSzVyPUCuNFg{PjJizszN MYDTRW5ITVJ?
IST-MES1 MnLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPMe3ZKSzVyPUCuNFg2PTJizszN NEDaTHFUSU6JRWK=
KALS-1 M4K4dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nuZmlEPTB;MD6wPVQ6KM7:TR?= MULTRW5ITVJ?
GCIY M3vRdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHwTWM2OD1yLkC5OlU3KM7:TR?= MULTRW5ITVJ?
RL95-2 NE\XSGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILWXJVKSzVyPUCuNVA{QCEQvF2= NFL1e5BUSU6JRWK=
TE-1 NGrNZYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnXTWM2OD1yLkGwOVQh|ryP MWLTRW5ITVJ?
NCI-H1355 Mn\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTBwMUGwNlgh|ryP NV;qcI0xW0GQR1XS
SW962 NXjrWVU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37zcGlEPTB;MD6xNVI6OiEQvF2= MULTRW5ITVJ?
KLE MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVKy[nJ[UUN3ME2wMlEyOzF5IN88US=> M{nx[HNCVkeHUh?=
MC116 M4jr[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3IOHJMUUN3ME2wMlEyPDFizszN Mn\WV2FPT0WU
NMC-G1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2CzVmlEPTB;MD6xNVYxPiEQvF2= M36wXXNCVkeHUh?=
KU812 NH:yXGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TJWGlEPTB;MD6xNVg5OyEQvF2= NH64SmRUSU6JRWK=
COLO-829 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIf3c4NKSzVyPUCuNVIzOTNizszN MYLTRW5ITVJ?
NTERA-S-cl-D1 NEPVUGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vWdmlEPTB;MD6xNlI5OyEQvF2= MUjTRW5ITVJ?
IST-MEL1 MoC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvvTWFKSzVyPUCuNVM1PSEQvF2= MXHTRW5ITVJ?
MLMA NIS3S4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3j6b2lEPTB;MD6xOFA{OiEQvF2= NULENWFXW0GQR1XS
LS-123 MkXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrjcXZKSzVyPUCuNVQxPjRizszN MlvEV2FPT0WU
LB2518-MEL NWHHZYdDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPGTWM2OD1yLkG0NVYzKM7:TR?= M3XFfXNCVkeHUh?=
NB69 MnH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{ntc2lEPTB;MD6xOFQ{PiEQvF2= M4nydnNCVkeHUh?=
8-MG-BA M{fYU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7tTWM2OD1yLkG1OFU5KM7:TR?= MXTTRW5ITVJ?
K5 NEnBNItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULJWJFtUUN3ME2wMlE3PDh7IN88US=> M{DOTnNCVkeHUh?=
KINGS-1 Mk\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTBwMU[2OlYh|ryP MnjWV2FPT0WU
SF268 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrZeWFGUUN3ME2wMlE4PDB2IN88US=> NFfxRlNUSU6JRWK=
PF-382 MnjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX:xVZRpUUN3ME2wMlE4Pjd6IN88US=> NXX3bZRpW0GQR1XS
SH-4 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTBwMUi0NVMh|ryP MXfTRW5ITVJ?
NALM-6 M3vF[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXqwTFVqUUN3ME2wMlE6Ojl3IN88US=> NV[zPZM6W0GQR1XS
CP66-MEL MofVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPoXpRKSzVyPUCuNVk2OzFizszN MmnxV2FPT0WU
697 NFqzZWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfHdHFKSzVyPUCuNVk6QDdizszN MmnZV2FPT0WU
CP67-MEL M{PhSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfuTWM2OD1yLkKwOFg5KM7:TR?= MX;TRW5ITVJ?
DSH1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTBwMkSwNFEh|ryP NHTGWVhUSU6JRWK=
HCE-4 M2i5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17KPWlEPTB;MD6yOlQ{QSEQvF2= NF7ITWJUSU6JRWK=
MZ2-MEL NVLudY5LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjNV29KSzVyPUCuNlg2OzdizszN MljVV2FPT0WU
BL-41 M4rINmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTYTVlKSzVyPUCuNlkyOjNizszN MXnTRW5ITVJ?
HUTU-80 MkDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTBwM{G0NkDPxE1? MUPTRW5ITVJ?
LOXIMVI NV3zcVF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vFOmlEPTB;MD6zNVUxOyEQvF2= MXjTRW5ITVJ?
no-10 NU\nW2JyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTBwM{G5N|Eh|ryP MUXTRW5ITVJ?
KARPAS-422 NGPMTWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTBwM{O5PVch|ryP Mn3kV2FPT0WU
SW684 M2e3OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV:4blBmUUN3ME2wMlM1QThizszN MWDTRW5ITVJ?
SF126 NIiyXXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPYbolKSzVyPUCuN|U1OSEQvF2= M1O1S3NCVkeHUh?=
D-263MG NUjFWXFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LHPWlEPTB;MD6zOlIzPCEQvF2= MmrNV2FPT0WU
OVCAR-4 MlPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPiO4RKSzVyPUCuN|c1OzNizszN MofWV2FPT0WU
BB49-HNC Moj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVH4end[UUN3ME2wMlM5PTl7IN88US=> MnXrV2FPT0WU
ONS-76 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXQS3dSUUN3ME2wMlQzQTVzIN88US=> MYLTRW5ITVJ?
MZ7-mel MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIToOIRKSzVyPUCuOFc6OTFizszN MWXTRW5ITVJ?
RCC10RGB MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnToTWM2OD1yLkS5NVEh|ryP NGTNOlRUSU6JRWK=
BOKU NXHPcZRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTBwNEmxN|Mh|ryP M1PsUHNCVkeHUh?=
no-11 NGHVXpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTBwNUCyNlgh|ryP Mof2V2FPT0WU
IST-SL2 NHf4dI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\MfoNiUUN3ME2wMlUxOzB{IN88US=> MlXLV2FPT0WU
RKO NGDNNnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTBwNUK5OlYh|ryP NWTldIN3W0GQR1XS
HT-144 MkL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTBwNUO2NFkh|ryP MXjTRW5ITVJ?
NCI-H446 Ml;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LPU2lEPTB;MD62Nlc3KM7:TR?= M4XCS3NCVkeHUh?=
QIMR-WIL MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXz1enRSUUN3ME2wMlcxPjJ7IN88US=> NFXwUJZUSU6JRWK=
MHH-PREB-1 NHq3O2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHTW|VKSzVyPUCuO|Q1PjlizszN NYnOeldtW0GQR1XS
EW-16 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHGNZVXUUN3ME2wMlc3OTd6IN88US=> MW\TRW5ITVJ?
EW-24 MnXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvrO41KSzVyPUCuO|gyPjVizszN NVTpO3ZZW0GQR1XS
LB373-MEL-D MnK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LNd2lEPTB;MD64NlUxQCEQvF2= M2e4bXNCVkeHUh?=
TE-9 NFPtbIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjrZ5FMUUN3ME2wMlg4PTN{IN88US=> MVPTRW5ITVJ?
A3-KAW MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fx[2lEPTB;MD65PFQ2OiEQvF2= M1H5T3NCVkeHUh?=
A101D NIHrXpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkm3TWM2OD1zLkCzNFQ{KM7:TR?= M{\McnNCVkeHUh?=
OCUB-M MkLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTFwMES0NVIh|ryP MlPjV2FPT0WU
ES4 NWDmUXZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPUfGhKSzVyPUGuNFUyPDVizszN MojvV2FPT0WU
TE-6 MlrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTFwMkGyNlYh|ryP NUj5TItUW0GQR1XS
D-502MG MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWmw[WpFUUN3ME2xMlI{Ozd4IN88US=> NF3ONVhUSU6JRWK=
KNS-42 NEW0Sm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlyyTWM2OD1zLkK0OFEzKM7:TR?= NHPZSGZUSU6JRWK=
SNU-C2B NHT4b5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnH0TWM2OD1zLkOwOVg6KM7:TR?= MWTTRW5ITVJ?
NCI-H1838 M3i0U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;YWGlEPTB;MT6zNFc{OyEQvF2= MUHTRW5ITVJ?
NKM-1 MmfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfKUFNKSzVyPUGuN|A5PTlizszN NVSwVWdqW0GQR1XS
GI-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;JS4hKSzVyPUGuN|YzOiEQvF2= MnPPV2FPT0WU
NB5 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTzPVE3UUN3ME2xMlM6QDJ5IN88US=> NWLm[YZIW0GQR1XS
CAS-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTFwNEC5PVIh|ryP MX3TRW5ITVJ?
HCE-T NFHS[o1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTFwNU[3NVQh|ryP MkHzV2FPT0WU
SBC-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jBR2lEPTB;MT61O|k5PCEQvF2= MXrTRW5ITVJ?
JiyoyeP-2003 NFzPPZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PiXWlEPTB;MT63N|Q3PiEQvF2= M2\qcHNCVkeHUh?=
TE-5 NUDrVmhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTFwN{mxN|kh|ryP NUnJ[GpvW0GQR1XS
CAN Mo\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTFwOEKyOVIh|ryP MlX3V2FPT0WU
SK-UT-1 NVHtb2JST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVKwS4Y{UUN3ME2yMlE3Pjl|IN88US=> M3TJUXNCVkeHUh?=
JVM-2 NEPOZ4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vDfmlEPTB;Mj6zOlI5PCEQvF2= NF7UU4FUSU6JRWK=
LB771-HNC M4q5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfWb3Y{UUN3ME2yMlU4PTVzIN88US=> NVjYd5dXW0GQR1XS
NCCIT M3TJZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LpVWlEPTB;Mj64OlYyPiEQvF2= MV7TRW5ITVJ?
NCI-H2126 MnrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHQTWM2OD1{Lki3OVUzKM7:TR?= NY\4[pZYW0GQR1XS
Calu-6 M1rPdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\xe2RKSzVyPUOuNFU4PDFizszN MWLTRW5ITVJ?
SK-LMS-1 M2T3TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLuVIpbUUN3ME2zMlEyQDh4IN88US=> MWnTRW5ITVJ?
ARH-77 M{Poe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2D6NWlEPTB;Mz60OlkyPSEQvF2= NVLnWW5PW0GQR1XS
NB17 NH;JSJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3Xze2lEPTB;Mz62N|g1PyEQvF2= NIDoOIxUSU6JRWK=
A253 NWXRTnl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTNwN{OyOFYh|ryP NHzJUI9USU6JRWK=
OPM-2 Ml3oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTRwMke2PFUh|ryP MU\TRW5ITVJ?
MV-4-11 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDVeI1KSzVyPUSuN|Y1PTRizszN NHrPTpZUSU6JRWK=
SR MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfwcmdTUUN3ME20MlQ6QTV2IN88US=> MVXTRW5ITVJ?
KG-1 MoHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE[2Vo9KSzVyPUSuOlA5PDVizszN NX24WpAxW0GQR1XS
OCI-AML2 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTVwOE[xOVQh|ryP MVnTRW5ITVJ?
D-247MG MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4[xfmlEPTB;Nj6xNlUyQSEQvF2= NHfTdWZUSU6JRWK=
DJM-1 NEjCPWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfRTWM2OD14LkS4OVU5KM7:TR?= MULTRW5ITVJ?
RPMI-6666 NGfONnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIftUGNKSzVyPUeuNlcxPjdizszN NEPU[2NUSU6JRWK=
KARPAS-45 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTdwNUG2O|Eh|ryP M360R3NCVkeHUh?=
LP-1 NVfTPWx{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nUW2lEPTB;Nz61OFc5OiEQvF2= MlzjV2FPT0WU
RS4-11 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTBTWM2OD15Lk[1O|g4KM7:TR?= M1T4OXNCVkeHUh?=
DU-4475 M{jLRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVT4NXlEUUN3ME24MlIyPjV{IN88US=> M{fmb3NCVkeHUh?=
MONO-MAC-6 NFn2TlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHoRXNKSzVyPUiuNlcxPjZizszN M3fnXHNCVkeHUh?=
NCI-SNU-16 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPTV2lKSzVyPUiuOVYyOjhizszN NHzoO|NUSU6JRWK=
SJSA-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRThwN{K4NFUh|ryP NV7yZoNtW0GQR1XS
MMAC-SF MlviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TySmlEPTB;OD63PVMxPyEQvF2= MljJV2FPT0WU
SK-NEP-1 Mn\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvYcYx[UUN3ME24Mlg6OTV3IN88US=> NXLpNW1mW0GQR1XS
J-RT3-T3-5 M1zoTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HKVWlEPTB;OD65OlUzQSEQvF2= M1XqRnNCVkeHUh?=
SKM-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfjeGZKSzVyPUmuNFE4OzRizszN MUXTRW5ITVJ?
LB2241-RCC MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13hcmlEPTB;OT6wNlAyOiEQvF2= NFfXT2NUSU6JRWK=
SIG-M5 M1fKXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInBVYhKSzVyPUmuNFI1QTNizszN M{DlWnNCVkeHUh?=
EVSA-T M2D0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{K2bWlEPTB;OT6yO|c6OyEQvF2= MlPEV2FPT0WU
GT3TKB NYjO[FZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDneHZjUUN3ME25MlM2PTR4IN88US=> MmrFV2FPT0WU
NB6 NGO4XnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjnbm5KSzVyPUmuPVIzPTlizszN MUHTRW5ITVJ?
EHEB NXjLd3ROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTwTWM2OD1zMD6wOlU3KM7:TR?= NXT5[W97W0GQR1XS
HEL MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\uXFhVUUN3ME2xNE41Pzd4IN88US=> MVPTRW5ITVJ?
ALL-PO NHHNUIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHKTWM2OD1zMD63PVM5KM7:TR?= NFvaRVVUSU6JRWK=
TGW NGm2TlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmK2TWM2OD1zMT6yPFI5KM7:TR?= MoPkV2FPT0WU
BC-3 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TmVGlEPTB;MUKuNVE{QCEQvF2= NVrFbWc1W0GQR1XS
IA-LM MlTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHwc2l1UUN3ME2xNk41PDR3IN88US=> MoH6V2FPT0WU
UACC-257 Mn7VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnjXJpkUUN3ME2xNk46OTl6IN88US=> NIrVcpRUSU6JRWK=
KP-N-YS MlfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTF{LkmyPFMh|ryP M3[xXHNCVkeHUh?=
Raji NVTNb4p7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fG[mlEPTB;MUOuO|Q6PyEQvF2= NVS5UVFzW0GQR1XS
SF539 M33xU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTF|Lki1OVch|ryP MWjTRW5ITVJ?
DMS-153 NXPEbVBJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHJ[5lPUUN3ME2xOE4xODJ6IN88US=> MY\TRW5ITVJ?
L-540 NULBb4M1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTF3LkC2O|Ih|ryP NUjhXmpvW0GQR1XS
MN-60 Mor2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\qcGlEPTB;MUWuNVk4QSEQvF2= MUHTRW5ITVJ?
RPMI-8866 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLwTWM2OD1zNz60OFU1KM7:TR?= M{n3VHNCVkeHUh?=
NCI-H510A M2Pme2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDuXI52UUN3ME2xPU4{QTd|IN88US=> NXXIcHZSW0GQR1XS
NB13 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXX4VpdEUUN3ME2xPU41QDd5IN88US=> MYLTRW5ITVJ?
HAL-01 M4DQe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\ZbmlEPTB;MUmuO|U1OyEQvF2= Ml7qV2FPT0WU
NCI-H720 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHwU4R{UUN3ME2yNE4zPzN|IN88US=> MWLTRW5ITVJ?
REH NGXoeWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\ZcGlEPTB;MkCuOlM2PyEQvF2= MWPTRW5ITVJ?
KNS-81-FD MlnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTJ|LkG0OkDPxE1? MVTTRW5ITVJ?
HC-1 NGDYVZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PucGlEPTB;MkSuOVU2OSEQvF2= NFX6NXpUSU6JRWK=
NCI-H2141 M1nLbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml31TWM2OD1{ND63O|U1KM7:TR?= MkjEV2FPT0WU
MOLT-4 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXWbG93UUN3ME2yOk43PzV|IN88US=> NHn6NXBUSU6JRWK=
OMC-1 NITVSmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnDUJVFUUN3ME2yO{4yPDJ{IN88US=> NITSS5ZUSU6JRWK=
LC-1F NUjYWldoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTJ5LkOyOFUh|ryP M1O2W3NCVkeHUh?=
NCI-H1304 NGTObnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHP5e|BKSzVyPUK4MlE3OjhizszN MYfTRW5ITVJ?
BC-1 NFHLNpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTJ6Lk[1NUDPxE1? MVHTRW5ITVJ?
NCI-H64 NWnEVpRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYS5PVdyUUN3ME2yPU43OjV|IN88US=> MlfXV2FPT0WU
MOLT-16 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFu3WZBKSzVyPUK5MlYzQTJizszN MX\TRW5ITVJ?
U-87-MG M3rPUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTVWpZKSzVyPUOwMlc3PiEQvF2= NF;rfZVUSU6JRWK=
GAK MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\iRWlEPTB;M{GuNlY5PiEQvF2= M1HPN3NCVkeHUh?=
ES8 NF\YWHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;W[pMxUUN3ME2zNk4yOjV{IN88US=> NESyPYpUSU6JRWK=
HCC1599 MnznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\sUlFKSzVyPUOyMlM{OjVizszN NEDl[GxUSU6JRWK=
EB-3 M2\meWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LL[2lEPTB;M{SuN|EyPyEQvF2= M2S3TnNCVkeHUh?=
HCC1187 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTN3LkiwOVIh|ryP NX3mV4Q6W0GQR1XS
SK-PN-DW MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnf6TWM2OD1|Nj6xPVQ{KM7:TR?= NYqwdJdHW0GQR1XS
JVM-3 NVPC[oRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfSbmpnUUN3ME2zO{4zOzN6IN88US=> MkLLV2FPT0WU
HCC2157 NF6zdodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkP6TWM2OD1|Nz65PVQ3KM7:TR?= M33DT3NCVkeHUh?=
A4-Fuk M{[3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLnPFRTUUN3ME2zPE4yODB7IN88US=> MlzvV2FPT0WU
COR-L279 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYexPVVjUUN3ME20NE4zQDVzIN88US=> NUPRW|ZyW0GQR1XS
DEL M3n6cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjWTWM2OD12MT65NFg3KM7:TR?= NIPlOXhUSU6JRWK=
NCI-H1395 MkD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTR{LkCxOlMh|ryP NHfESGdUSU6JRWK=
MHH-NB-11 MlzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljFTWM2OD12Mz6wPFE5KM7:TR?= NUfhSmZ6W0GQR1XS
NCI-H2107 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTR|LkS4OFYh|ryP NITwVmdUSU6JRWK=
NEC8 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTR2LkOzOkDPxE1? Mkf3V2FPT0WU
COLO-684 NIrwU5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3mTWM2OD12Nj6yNlU5KM7:TR?= NWfpW3BPW0GQR1XS
LS-411N NVfjRXpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTR6LkS3OFgh|ryP NEG4R4VUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. [3]

Protocol

Kinase Assay:

[1]

+ Expand

Kinase autophosphorylation assays:

Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.
Cell Research:

[1]

+ Expand
  • Cell lines: Ba/F3 cell lines
  • Concentrations: ~32 nM
  • Incubation Time: 72 hours
  • Method:

    Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC)
  • Formulation: DMSO
  • Dosages: 30 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 98 mg/mL (200.81 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 488.01
Formula

C22H26ClN7O2S

CAS No. 302962-49-8
Storage powder
Synonyms BMS-354825

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01445509 Active, not recruiting Solid Tumors National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 27, 2008 Phase 1
NCT03041701 Not yet recruiting Rhabdomyosarcoma|Rhabdomyosarcoma- Alveolar|Rhabdomyosarcoma-Embryonal National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 24, 2017 Phase 1|Phase 2
NCT03023046 Not yet recruiting Adult Acute Lymphoblastic Leukemia|Adult Lymphoblastic Lymphoma|CD20 Positive|Philadelphia Chromosome Positive University of Washington|National Cancer Institute (NCI) February 2017 Phase 2
NCT03020030 Not yet recruiting Acute Lymphoblastic Leukemia, Pediatric Dana-Farber Cancer Institute|Baxalta US Inc. January 2017 Phase 3
NCT02744768 Not yet recruiting Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dellAdulto December 2016 Phase 2
NCT02923986 Not yet recruiting Chronic Myelogenous Leukemia, Ph1-Positive Bio-Path Holdings, Inc. November 2016 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    what’s the difference between S1021 and S7782? Which one is better for in vivo studies?

  • Answer:

    Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).

  • Question 2:

    Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?

  • Answer:

    Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Related Src Products

Tags: buy Dasatinib | Dasatinib supplier | purchase Dasatinib | Dasatinib cost | Dasatinib manufacturer | order Dasatinib | Dasatinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID